AnandAshwinPatelMD(He/Him)
Hematology • Chicago, ILHematologic Oncology, Myeloproliferative Disorder Hematology-Oncology
Assistant Professor, Director of Inpatient Leukemia Service
Dr. Patel is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5841 S Maryland Ave
Chicago, IL 60637Phone+1 888-824-0200
Summary
- Dr. Patel an expert in the treatment of myeloproliferative diseases, myelodysplastic syndromes, and leukemias. He is an active researcher whose work is focused on the development of clinical trials to investigate novel therapies that may improve the standard of care for patients with myeloid cancers and leukemia. Dr. Patel has published his research in several well-respected peer-reviewed journals including Blood, Blood Advances, British Journal of Haematology, Cancer, JCI Insight, and Bone Marrow Transplantation.
Education & Training
University of ChicagoFellowship, Hematology and Medical Oncology, 2018 - 2021
McGaw Medical Center of Northwestern UniversityChief Residency, Internal Medicine, 2017 - 2018- McGaw Medical Center of Northwestern UniversityResidency, Internal Medicine, 2014 - 2017
University of Missouri-Columbia School of MedicineClass of 2014
Certifications & Licensure
IL State Medical License 2014 - 2023- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- 40 Under 40 in Cancer Amplity Health, Swim Across America, The National Community Oncology Dispensing Association, Inc. (NCODA), and the Association for Value-Based Cancer Care, 2024
- Medical Alumni Outstanding Young Physician Award University of Missouri School of Medicine, 2024
- Clinical Research Training Institute Participant American Society of Hematology, 2021
- Join now to see all
Clinical Trials
- Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO) Start of enrollment: 2021 Mar 02
- A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) Start of enrollment: 2022 Aug 05
- A Study of Oral TP-3654 in Patients With Myelofibrosis Start of enrollment: 2019 Dec 16
- Join now to see all
Publications & Presentations
PubMed
- 46 citationsStructural racism is a mediator of disparities in acute myeloid leukemia outcomes.Ivy Elizabeth Abraham, Garth H Rauscher, Anand Ashwin Patel, William B Pearse, Priya Rajakumar
Blood. 2022-04-07 - 7 citationsPhase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia.Farhad Ravandi, Asad Bashey, James Foran, Wendy Stock, Raya Mawad
Blood Advances. 2023-11-14 - 1 citationsReal-world outcomes of intensive induction approaches in core binding factor acute myeloid leukemia.Alexandra E Rojek, Benjamin J McCormick, Joanna Cwykiel, Oluwatobi Odetola, Yasmin Abaza
Ejhaem. 2024-08-01
Press Mentions
Expert Point of View: Anand Ashwin Patel, MDAugust 10th, 2023
2023 ASCO ANNUAL MEETING Luspatercept Poised to Become a New First-Line Standard of Care for Transfusion-Dependent, Lower-Risk Myelodysplastic SyndromesJune 2nd, 2023
Professional Memberships
- Member
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
